Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SIGA Technologies, Inc. (SIGA)
USD3.49
+0.07 (+1.94%)
US NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
Address
31 East 62nd Street 10065
New York City, NY, US
New York City, NY, US
CEO
Diem Nguyen
Website
siga.com
IPO
1997-09-10
CIK 1010086 ISIN US8269171067
Description
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.49
+0.07 (+1.94%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
561.3K
Beta
0.89
Float Shares
40.55M
Free Float %
56.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.21% | -4.21% | +4.36% | -31.89% | -26.73% | -25.53% | -23.40% | -23.01% | -33.28% | +448.19% | -13.33% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
3.49
DCF (Unlevered)
10.29
+195.0%
DCF (Levered)
10.11
+189.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.90
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
A+
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
3 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-31.8% Q1'26: -11.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-60.2% Q1'26: -745.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+26.5% Q1'26: -138.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+25.1% ★ Q1'26: -85.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+40.9% ★ Q1'26: -271.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.2% ★ Q1'26: +0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.02× ★ Q1'26: -0.03× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
8.18M
est: 93.38M (-91.2%)
|
14.99M
est: 93.38M (-83.9%)
|
12.27M
est: 90.00M (-86.4%)
|
477.05M
est: 117.00M (+307.7%)
|
26.74M
est: 144.00M (-81.4%)
|
133.67M
est: 133.31M (+0.3%)
|
110.78M
est: 115.38M (-4.0%)
|
139.92M
est: 172.60M (-18.9%)
|
138.72M
est: 160.21M (-13.4%)
|
94.60M
est: 97.50M (-3.0%)
|
66.31M
66.31M – 66.31M
-32.0% YoY
|
215.39M
215.39M – 215.39M
+224.8% YoY
|
| EBITDA |
-38.48M
est: 52.05M (-173.9%)
|
-25.45M
est: 52.05M (-148.9%)
|
-23.44M
est: 50.17M (-146.7%)
|
355.17M
est: 65.22M (+444.6%)
|
6.12M
est: 80.27M (-92.4%)
|
89.62M
est: 74.31M (+20.6%)
|
43.22M
est: 64.31M (-32.8%)
|
84.16M
est: 96.21M (-12.5%)
|
70.52M
est: 77.76M (-9.3%)
|
24.26M
est: 47.33M (-48.7%)
|
32.19M
32.19M – 32.19M
-32.0% YoY
|
104.55M
104.55M – 104.55M
+224.8% YoY
|
| EBIT |
-38.72M
est: 51.66M (-174.9%)
|
-25.62M
est: 51.66M (-149.6%)
|
-23.57M
est: 49.80M (-147.3%)
|
427.12M
est: 64.74M (+559.8%)
|
5.59M
est: 79.68M (-93.0%)
|
89.09M
est: 73.76M (+20.8%)
|
42.70M
est: 63.84M (-33.1%)
|
83.62M
est: 95.50M (-12.4%)
|
69.98M
est: 77.05M (-9.2%)
|
23.70M
est: 46.89M (-49.5%)
|
31.89M
31.89M – 31.89M
-32.0% YoY
|
103.59M
103.59M – 103.59M
+224.8% YoY
|
| Net Income |
-39.45M
est: 58.85M (-167.0%)
|
-39.70M
est: 58.85M (-167.5%)
|
-36.24M
|
421.81M
|
-7.24M
|
69.45M
est: 63.15M (+10.0%)
|
33.90M
est: 47.37M (-28.4%)
|
68.07M
est: 77.51M (-12.2%)
|
59.21M
est: 75.19M (-21.2%)
|
23.30M
est: 47.98M (-51.4%)
|
121.73M
121.73M – 121.73M
+153.7% YoY
|
105.26M
105.26M – 105.26M
-13.5% YoY
|
| SGA |
10.58M
est: 16.97M (-37.6%)
|
13.71M
est: 16.97M (-19.2%)
|
12.30M
est: 16.35M (-24.8%)
|
12.88M
est: 21.26M (-39.4%)
|
13.25M
est: 26.16M (-49.4%)
|
18.03M
est: 24.22M (-25.6%)
|
35.12M
est: 20.96M (+67.5%)
|
22.04M
est: 31.36M (-29.7%)
|
25.14M
est: 26.39M (-4.8%)
|
3.13M
est: 16.06M (-80.5%)
|
10.92M
10.92M – 10.92M
-32.0% YoY
|
35.48M
35.48M – 35.48M
+224.8% YoY
|
| EPS |
-0.73
est: 0.82 (-189.0%)
|
-0.69
est: 0.82 (-184.1%)
|
-0.46
|
5.28
|
-0.09
|
0.92
est: 0.88 (+4.5%)
|
0.46
est: 0.66 (-30.3%)
|
0.95
est: 1.08 (-12.0%)
|
0.83
est: 1.05 (-21.0%)
|
0.33
est: 0.67 (-50.7%)
|
1.70
1.70 – 1.70
+153.7% YoY
|
1.47
1.47 – 1.47
-13.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-06 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-05 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-01 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
32.58M
OE per share TTM
0.45
Owner's Yield
9.61%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1.6%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
38
Total invested
4.78M
Insider transactions (90d)
0
Beneficial owners (>5%)
21
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Daniel Mack | 6.07M | 7.70% | — | 6.07M | — | — | HC | USA | 2017-02-14 | ↗ |
| 2 | Nantahala Capital Management, LLC | 6.07M | 7.70% | — | 6.07M | — | — | IA | MA | 2017-02-14 | ↗ |
| 3 | Wilmot B. Harkey | 6.07M | 7.70% | — | 6.07M | — | — | HC | USA | 2017-02-14 | ↗ |
| 4 | (1) BlackRock, Inc. | 4.02M | 5.60% | 3.81M | — | 4.02M | — | HC | Delaware | 2024-11-08 | ↗ |
| 5 | Andrew Sole | 3.95M | 5.00% | 109.6K | 3.84M | — | 3.84M | IN | United States of America | 2017-11-29 | ↗ |
| 6 | D. E. Shaw & Co., L.P. | 3.63M | 5.00% | — | 3.63M | — | — | IA, PN | Delaware | 2022-06-24 | ↗ |
| 7 | David E. Shaw | 3.63M | 5.00% | — | 3.63M | — | — | IN | United States | 2022-06-24 | ↗ |
| 8 | Andrew L. Sole | 3.11M | 4.00% | 145.3K | 2.96M | 145.3K | 2.96M | IN | — | 2021-02-23 | ↗ |
| 9 | Alan S. Cooper | 3.05M | 3.80% | — | 3.05M | — | — | IN | United States | 2019-02-14 | ↗ |
| 10 | Jet Capital Investors, L.P. | 3.05M | 3.80% | — | 3.05M | — | — | IA | State of Delaware | 2019-02-14 | ↗ |
| 11 | Matthew Mark | 3.05M | 3.80% | — | 3.05M | — | — | IN | United States | 2019-02-14 | ↗ |
| 12 | 13G | 2.95M | 5.50% | 2.95M | — | 2.95M | — | IA | State of Oklahoma | 2015-02-17 | ↗ |
| 13 | Jet Capital Management, L.L.C. | 2.46M | 3.06% | — | 2.46M | — | — | OO | State of Delaware | 2019-02-14 | ↗ |
| 14 | Jet Capital Master Fund, LP | 2.46M | 3.06% | — | 2.46M | — | — | PN | Cayman Islands | 2019-02-14 | ↗ |
| 15 | Esopus Creek Value Series Fund LP – Series A | 2.36M | 3.10% | — | 2.36M | — | 2.36M | OO | — | 2021-02-23 | ↗ |
| 16 | Paul Saunders, Jr. | 2.30M | 3.00% | 10.0K | 2.29M | 10.0K | 2.29M | IN | — | 2021-02-23 | ↗ |
| 17 | 13G/A | 2.04M | 3.80% | — | 13.00 | — | 2.04M | PN | U.S. Citizen | 2016-01-29 | ↗ |
| 18 | Hutch Capital Management LLC | 786.3K | 1.00% | — | 786.3K | — | 786.3K | OO | — | 2021-02-23 | ↗ |
| 19 | Hutch Master Fund Ltd. | 786.3K | 1.00% | — | 786.3K | — | 786.3K | OO | — | 2021-02-23 | ↗ |
| 20 | Esopus Creek Management LLC | 598.1K | 1.00% | — | 598.1K | — | 598.1K | OO | — | 2021-02-23 | ↗ |
| 21 | Rainy Daze LLC | 598.1K | 1.00% | — | 598.1K | — | 598.1K | OO | — | 2021-02-23 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
38
-162 vs prev Q
New positions
4
Closed positions
164
Increased
17
Reduced
13
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 244.9K +244.9K (+100.0%) | 1.50B +1.5B (+100.0%) | 0.34% +0.342 pp | 0.00% +0.002 pp | USD6.11 +0.0% | 1 qtrs NEW |
| 2 | BLACKROCK, INC. | 3.59M +63.3K (+1.8%) | 21.93M -10.3M (-32.0%) | 5.01% +0.079 pp | 0.00% 0.000 pp | USD6.74 -9.3% | 6 qtrs — |
| 3 | VANGUARD GROUP INC | 2.72M +67.8K (+2.6%) | 16.64M -7.7M (-31.5%) | 3.80% +0.088 pp | 0.00% 0.000 pp | USD6.50 -6.0% | 31 qtrs — |
| 4 | DIMENSIONAL FUND ADVISORS LP | 2.54M +104.4K (+4.3%) | 15.50M -6.8M (-30.4%) | 3.54% +0.139 pp | 0.00% -0.002 pp | USD6.43 -5.0% | 29 qtrs — |
| 5 | ALTRAVUE CAPITAL, LLC | 2.41M -8.7K (-0.4%) | 14.72M -7.4M (-33.5%) | 3.36% -0.019 pp | 1.21% -0.622 pp | USD6.84 -10.7% | 29 qtrs — |
| 6 | AMERICAN CENTURY COMPANIES INC | 1.17M -67.2K (-5.5%) | 7.12M -4.2M (-36.9%) | 1.63% -0.097 pp | 0.00% -0.002 pp | USD7.39 -17.3% | 18 qtrs — |
| 7 | STATE STREET CORP | 1.08M +41.7K (+4.0%) | 6.57M -2.9M (-30.5%) | 1.50% +0.055 pp | 0.00% 0.000 pp | USD7.23 -15.5% | 31 qtrs — |
| 8 | CITADEL ADVISORS LLC | 1.04M -82.1K (-7.3%) | 6.37M -3.9M (-38.1%) | 1.46% -0.118 pp | 0.00% -0.001 pp | USD6.55 -6.7% | 30 qtrs — |
| 9 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.03M +190.4K (+22.8%) | 6.26M -1.4M (-18.0%) | 1.43% +0.264 pp | 0.00% -0.001 pp | USD7.65 -20.1% | 8 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.00M +6.5K (+0.7%) | 6.14M -3.0M (-32.8%) | 1.40% +0.006 pp | 0.00% 0.000 pp | USD5.98 +2.2% | 31 qtrs — |
| 11 | JUPITER ASSET MANAGEMENT LTD | 990.6K +— (+0.0%) | 6.05M -3.0M (-33.2%) | 1.38% -0.003 pp | 0.05% -0.029 pp | USD7.46 -18.1% | 14 qtrs — |
| 12 | AQR CAPITAL MANAGEMENT LLC | 872.8K +524.7K (+150.7%) | 5.33M +2.1M (+67.4%) | 1.22% +0.732 pp | 0.00% +0.001 pp | USD7.26 -15.8% | 3 qtrs — |
| 13 | HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | 819.4K -8.1K (-1.0%) | 5.01M -2.6M (-33.9%) | 1.14% -0.014 pp | 0.02% -0.008 pp | USD6.03 +1.3% | 10 qtrs — |
| 14 | FIRST WILSHIRE SECURITIES MANAGEMENT INC | 684.1K -3.8K (-0.6%) | 4.18M -2.1M (-33.6%) | 0.96% -0.007 pp | 1.05% -0.623 pp | USD6.09 +0.3% | 15 qtrs — |
| 15 | GOLDMAN SACHS GROUP INC | 647.1K +115.0K (+21.6%) | 3.95M -915.0K (-18.8%) | 0.90% +0.159 pp | 0.00% 0.000 pp | USD6.03 +1.3% | 32 qtrs — |
| 16 | BANK OF AMERICA CORP /DE/ | 641.4K +122.7K (+23.6%) | 3.92M -827.7K (-17.4%) | 0.90% +0.170 pp | 0.00% +0.000 pp | USD6.68 -8.5% | 32 qtrs — |
| 17 | CSM ADVISORS, LLC | 627.9K +31.4K (+5.3%) | 3.84M -1.6M (-29.7%) | 0.88% +0.042 pp | 0.10% -0.048 pp | USD7.50 -18.5% | 3 qtrs — |
| 18 | ROYCE & ASSOCIATES LP | 611.0K -69.2K (-10.2%) | 3.73M -2.5M (-40.0%) | 0.85% -0.099 pp | 0.04% -0.024 pp | USD6.61 -7.6% | 20 qtrs — |
| 19 | LEGATO CAPITAL MANAGEMENT LLC | 580.5K +68.5K (+13.4%) | 3.55M -1.1M (-24.3%) | 0.81% +0.094 pp | 0.31% -0.205 pp | USD5.54 +10.3% | 11 qtrs — |
| 20 | NEW YORK STATE COMMON RETIREMENT FUND | 570.6K +— (+0.0%) | 3.49M -1.7M (-33.2%) | 0.80% -0.002 pp | 0.00% -0.002 pp | USD6.63 -7.8% | 31 qtrs — |
| 21 | D. E. SHAW & CO., INC. | 554.6K +54.8K (+11.0%) | 3.39M -1.2M (-25.9%) | 0.77% +0.075 pp | 0.00% -0.001 pp | USD9.13 -33.1% | 22 qtrs — |
| 22 | LSV ASSET MANAGEMENT | 538.6K +120.3K (+28.8%) | 3.29M -537.0K (-14.0%) | 0.75% +0.167 pp | 0.01% -0.001 pp | USD6.34 -3.6% | 7 qtrs — |
| 23 | JACOBS LEVY EQUITY MANAGEMENT, INC | 496.2K +32.5K (+7.0%) | 3.03M -1.2M (-28.5%) | 0.69% +0.044 pp | 0.01% -0.005 pp | USD6.62 -7.7% | 3 qtrs — |
| 24 | MORGAN STANLEY | 494.5K -162.5K (-24.7%) | 3.02M -3.0M (-49.7%) | 0.69% -0.229 pp | 0.00% 0.000 pp | USD7.41 -17.5% | 32 qtrs — |
| 25 | MILLENNIUM MANAGEMENT LLC | 489.3K +233.0K (+90.9%) | 2.99M +644.2K (+27.5%) | 0.68% +0.325 pp | 0.00% +0.000 pp | USD7.42 -17.7% | 22 qtrs — |
| 26 | UNIPLAN INVESTMENT COUNSEL, INC. | 395.9K -622.0 (-0.2%) | 2.42M -1.2M (-33.3%) | 0.55% -0.002 pp | 0.24% -0.113 pp | USD6.54 -6.6% | 15 qtrs — |
| 27 | RENAISSANCE TECHNOLOGIES LLC | 378.1K +69.6K (+22.6%) | 2.31M -512.6K (-18.2%) | 0.53% +0.096 pp | 0.00% 0.000 pp | USD6.13 -0.3% | 28 qtrs — |
| 28 | NORTHERN TRUST CORP | 375.8K -17.0K (-4.3%) | 2.30M -1.3M (-36.1%) | 0.52% -0.025 pp | 0.00% 0.000 pp | USD5.97 +2.3% | 32 qtrs — |
| 29 | DENALI ADVISORS LLC | 361.8K +1.5K (+0.4%) | 2.21M -1.1M (-32.9%) | 0.51% +0.001 pp | 0.25% -0.127 pp | USD6.93 -11.8% | 7 qtrs — |
| 30 | VICTORY CAPITAL MANAGEMENT INC | 339.9K -17.9K (-5.0%) | 2.08M -1.2M (-36.6%) | 0.47% -0.026 pp | 0.00% -0.001 pp | USD7.26 -15.8% | 26 qtrs — |
| 31 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 316.7K -32.7K (-9.4%) | 1.94M -1.3M (-39.5%) | 0.44% -0.047 pp | 0.00% 0.000 pp | USD8.09 -24.5% | 31 qtrs — |
| 32 | ACADIAN ASSET MANAGEMENT LLC | 294.2K +208.7K (+244.2%) | 1.79M +1.0M (+130.3%) | 0.41% +0.291 pp | 0.00% +0.002 pp | USD6.99 -12.6% | 2 qtrs — |
| 33 | SEGALL BRYANT & HAMILL, LLC | 274.0K -6.6K (-2.4%) | 1.67M -893.7K (-34.8%) | 0.38% -0.010 pp | 0.02% -0.012 pp | USD7.54 -19.0% | 7 qtrs — |
| 34 | BANK OF NEW YORK MELLON CORP | 254.2K -16.2K (-6.0%) | 1.55M -920.6K (-37.2%) | 0.36% -0.023 pp | 0.00% 0.000 pp | USD6.42 -4.8% | 31 qtrs — |
| 35 | MACQUARIE GROUP LTD | 244.9K -39.4K (-13.9%) | 1.50M -1.1M (-42.5%) | 0.34% -0.056 pp | 0.01% +0.004 pp | USD6.20 -1.5% | 10 qtrs — |
| 36 | STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 239.0K +121.3K (+103.1%) | 1.46M +383.5K (+35.6%) | 0.33% +0.169 pp | 0.00% +0.001 pp | USD7.48 -18.3% | 11 qtrs — |
| 37 | STATE OF WISCONSIN INVESTMENT BOARD | 215.3K +14.0 (+0.0%) | 1.32M -654.4K (-33.2%) | 0.30% -0.001 pp | 0.00% -0.002 pp | USD7.10 -13.9% | 17 qtrs — |
| 38 | AMERIPRISE FINANCIAL INC | 198.0K +25.5K (+14.8%) | 1.21M -368.4K (-23.3%) | 0.28% +0.035 pp | 0.00% 0.000 pp | USD5.82 +5.0% | 12 qtrs — |
| 39 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 197.9K -20.0K (-9.2%) | 1.21M -784.5K (-39.4%) | 0.28% -0.029 pp | 0.03% -0.017 pp | USD7.80 -21.7% | 3 qtrs — |
| 40 | JANUS HENDERSON GROUP PLC | 188.7K -100.4K (-34.7%) | 1.15M -1.5M (-56.4%) | 0.26% -0.141 pp | 0.00% -0.001 pp | USD9.16 -33.3% | 15 qtrs — |
| 41 | JPMORGAN CHASE & CO | 185.0K -26.1K (-12.4%) | 1.13M -801.0K (-41.5%) | 0.26% -0.037 pp | 0.00% +0.000 pp | USD8.89 -31.3% | 31 qtrs — |
| 42 | BRANDYWINE GLOBAL INVESTMENT MANAGEMENT, LLC | 175.0K -6.6K (-3.6%) | 1.07M -592.5K (-35.7%) | 0.24% -0.010 pp | 0.01% -0.004 pp | USD9.15 -33.2% | 2 qtrs — |
| 43 | QUBE RESEARCH & TECHNOLOGIES LTD | 164.8K +118.6K (+256.9%) | 1.01M +584.5K (+138.3%) | 0.23% +0.166 pp | 0.00% +0.001 pp | USD6.96 -12.2% | 2 qtrs — |
| 44 | FIRST TRUST ADVISORS LP | 154.9K +3.3K (+2.2%) | 946.7K -440.8K (-31.8%) | 0.22% +0.004 pp | 0.00% 0.000 pp | USD5.77 +5.9% | 14 qtrs — |
| 45 | FEDERATED HERMES, INC. | 139.5K -209.7K (-60.0%) | 852.4K -2.3M (-73.3%) | 0.19% -0.294 pp | 0.00% -0.004 pp | USD5.72 +6.8% | 13 qtrs — |
| 46 | WELLINGTON MANAGEMENT GROUP LLP | 128.0K -15.1K (-10.6%) | 781.9K -527.5K (-40.3%) | 0.18% -0.022 pp | 0.00% 0.000 pp | USD6.31 -3.2% | 6 qtrs — |
| 47 | UBS ASSET MANAGEMENT AMERICAS INC | 127.8K +— (+0.0%) | 781.0K -388.6K (-33.2%) | 0.18% 0.000 pp | 0.00% 0.000 pp | USD6.54 -6.6% | 25 qtrs — |
| 48 | SUMMERHAVEN INVESTMENT MANAGEMENT, LLC | 122.7K +— (+0.0%) | 749.8K -373.0K (-33.2%) | 0.17% 0.000 pp | 0.43% -0.229 pp | USD7.19 -15.0% | 6 qtrs — |
| 49 | JANE STREET GROUP, LLC | 120.9K +12.3K (+11.3%) | 738.4K -254.8K (-25.7%) | 0.17% +0.017 pp | 0.00% +0.000 pp | USD6.21 -1.6% | 19 qtrs — |
| 50 | INVESCO LTD. | 113.4K +8.2K (+7.8%) | 693.1K -270.2K (-28.0%) | 0.16% +0.011 pp | 0.00% +0.000 pp | USD8.62 -29.1% | 26 qtrs — |
| 51 | INTEGRATED QUANTITATIVE INVESTMENTS LLC | 104.6K +104.6K (+100.0%) | 639.4K +639.4K (+100.0%) | 0.15% +0.146 pp | 0.14% +0.137 pp | USD6.11 +0.0% | 1 qtrs NEW |
| 52 | NUVEEN, LLC | 100.1K +— (+0.0%) | 611.6K -304.3K (-33.2%) | 0.14% 0.000 pp | 0.00% 0.000 pp | USD5.48 +11.5% | 4 qtrs — |
| 53 | WINTON GROUP LTD | 97.4K -8.2K (-7.8%) | 595.0K -371.1K (-38.4%) | 0.14% -0.012 pp | 0.02% -0.016 pp | USD9.15 -33.2% | 2 qtrs — |
| 54 | PRUDENTIAL FINANCIAL INC | 96.9K +13.5K (+16.2%) | 592.0K -171.0K (-22.4%) | 0.14% +0.019 pp | 0.00% 0.000 pp | USD8.73 -30.0% | 2 qtrs — |
| 55 | KLP KAPITALFORVALTNING AS | 96.2K +8.6K (+9.8%) | 587.8K -213.8K (-26.7%) | 0.13% +0.012 pp | 0.00% -0.001 pp | USD6.23 -1.9% | 5 qtrs — |
| 56 | MARTINGALE ASSET MANAGEMENT L P | 92.3K -13.4K (-12.7%) | 563.7K -403.1K (-41.7%) | 0.13% -0.019 pp | 0.01% -0.010 pp | USD6.76 -9.6% | 7 qtrs — |
| 57 | STRS OHIO | 90.1K +23.7K (+35.7%) | 550.5K -57.0K (-9.4%) | 0.13% +0.033 pp | 0.00% 0.000 pp | USD8.11 -24.7% | 31 qtrs — |
| 58 | SWISS NATIONAL BANK | 83.9K +— (+0.0%) | 512.6K -255.1K (-33.2%) | 0.12% 0.000 pp | 0.00% 0.000 pp | USD5.08 +20.3% | 25 qtrs — |
| 59 | STATE OF WYOMING | 82.9K +24.4K (+41.7%) | 506.8K -28.6K (-5.3%) | 0.12% +0.034 pp | 0.06% -0.006 pp | USD6.65 -8.1% | 17 qtrs — |
| 60 | AVIVA PLC | 78.9K +23.3K (+41.8%) | 482.0K -26.9K (-5.3%) | 0.11% +0.032 pp | 0.00% 0.000 pp | USD7.06 -13.5% | 8 qtrs — |
| 61 | BARCLAYS PLC | 77.3K -487.0 (-0.6%) | 472.5K -52.8K (-10.0%) | 0.11% -0.001 pp | 0.00% +0.000 pp | USD6.65 -8.1% | 32 qtrs — |
| 62 | CANADA PENSION PLAN INVESTMENT BOARD | 75.0K +75.0K (+100.0%) | 458.3K +458.3K (+100.0%) | 0.10% +0.105 pp | 0.00% +0.000 pp | USD6.11 +0.0% | 1 qtrs NEW |
| 63 | CREATIVE PLANNING | 72.3K +15.3K (+26.9%) | 441.6K -79.5K (-15.3%) | 0.10% +0.021 pp | 0.00% 0.000 pp | USD6.90 -11.4% | 10 qtrs — |
| 64 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 65.9K +5.5K (+9.1%) | 439.2K -70.8K (-13.9%) | 0.09% +0.008 pp | 0.00% 0.000 pp | USD6.55 -6.7% | 3 qtrs — |
| 65 | PRECISION WEALTH STRATEGIES, LLC | 67.8K +67.8K (+100.0%) | 414.2K +414.2K (+100.0%) | 0.09% +0.095 pp | 0.13% +0.134 pp | USD6.11 +0.0% | 1 qtrs NEW |
| 66 | PRINCIPAL FINANCIAL GROUP INC | 63.8K +19.8K (+45.0%) | 389.7K -12.8K (-3.2%) | 0.09% +0.028 pp | 0.00% +0.000 pp | USD6.94 -12.0% | 21 qtrs — |
| 67 | ALLIANCEBERNSTEIN L.P. | 63.7K +— (+0.0%) | 389.3K -193.7K (-33.2%) | 0.09% 0.000 pp | 0.00% 0.000 pp | USD6.58 -7.1% | 31 qtrs — |
| 68 | LOS ANGELES CAPITAL MANAGEMENT LLC | 46.6K +1.1K (+2.4%) | 386.9K -29.0K (-7.0%) | 0.07% +0.001 pp | 0.00% 0.000 pp | USD5.84 +4.6% | 24 qtrs — |
| 69 | FRANKLIN RESOURCES INC | 60.1K -20.1K (-25.1%) | 367.4K -366.8K (-50.0%) | 0.08% -0.028 pp | 0.00% 0.000 pp | USD6.81 -10.3% | 22 qtrs — |
| 70 | TREXQUANT INVESTMENT LP | 57.6K +12.3K (+27.1%) | 351.9K -62.7K (-15.1%) | 0.08% +0.017 pp | 0.00% -0.001 pp | USD8.50 -28.1% | 2 qtrs — |
| 71 | MAN GROUP PLC | 57.5K +10.4K (+21.9%) | 351.6K -80.2K (-18.6%) | 0.08% +0.014 pp | 0.00% 0.000 pp | USD6.30 -3.0% | 4 qtrs — |
| 72 | CAMPBELL & CO INVESTMENT ADVISER LLC | 55.6K -27.8K (-33.3%) | 340.0K -423.2K (-55.5%) | 0.08% -0.039 pp | 0.02% -0.041 pp | USD6.35 -3.8% | 12 qtrs — |
| 73 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 54.0K +21.1K (+64.2%) | 330.0K +29.0K (+9.6%) | 0.08% +0.029 pp | 0.00% -0.001 pp | USD7.96 -23.2% | 2 qtrs — |
| 74 | RHUMBLINE ADVISERS | 53.6K -10.7K (-16.6%) | 327.7K -261.0K (-44.3%) | 0.07% -0.015 pp | 0.00% 0.000 pp | USD6.95 -12.1% | 31 qtrs — |
| 75 | JAMES INVESTMENT RESEARCH INC | 53.5K +— (+0.0%) | 327.2K -162.8K (-33.2%) | 0.07% 0.000 pp | 0.04% -0.018 pp | USD7.08 -13.7% | 16 qtrs — |
| 76 | VESTCOR INC | 53.3K +38.7K (+265.1%) | 326.0K +192.0K (+143.3%) | 0.07% +0.054 pp | 0.01% +0.005 pp | USD6.94 -12.0% | 5 qtrs — |
| 77 | ALPS ADVISORS INC | 51.7K +568.0 (+1.1%) | 315.8K -151.9K (-32.5%) | 0.07% +0.001 pp | 0.00% -0.001 pp | USD9.12 -33.0% | 2 qtrs — |
| 78 | STRATEGIC BLUEPRINT, LLC | 51.1K +51.1K (+100.0%) | 312.2K +312.2K (+100.0%) | 0.07% +0.071 pp | 0.02% +0.018 pp | USD6.11 +0.0% | 1 qtrs NEW |
| 79 | DGS CAPITAL MANAGEMENT, LLC | 50.4K +17.1K (+51.4%) | 307.8K +3.4K (+1.1%) | 0.07% +0.024 pp | 0.05% -0.003 pp | USD6.40 -4.5% | 6 qtrs — |
| 80 | SKOPOS LABS, INC. | 49.2K +49.2K (+100.0%) | 307.4K +307.4K (+100.0%) | 0.07% +0.069 pp | 0.01% +0.014 pp | USD6.11 +0.0% | 5 qtrs — |
| 81 | DAVENPORT & CO LLC | 50.0K +50.0K (+100.0%) | 305.5K +305.5K (+100.0%) | 0.07% +0.070 pp | 0.00% +0.002 pp | USD6.11 +0.0% | 32 qtrs — |
| 82 | O'SHAUGHNESSY ASSET MANAGEMENT, LLC | 49.7K +4.9K (+10.8%) | 303.4K -106.5K (-26.0%) | 0.07% +0.007 pp | 0.00% -0.001 pp | USD8.85 -31.0% | 2 qtrs — |
| 83 | LAZARD ASSET MANAGEMENT LLC | 47.8K +31.6K (+195.5%) | 291.9K +144.0K (+97.4%) | 0.07% +0.044 pp | 0.00% +0.000 pp | USD7.14 -14.4% | 8 qtrs — |
| 84 | PRICE T ROWE ASSOCIATES INC /MD/ | 46.3K +3.6K (+8.4%) | 284.0K -108.0K (-27.6%) | 0.06% +0.005 pp | 0.00% +0.000 pp | USD6.77 -9.7% | 20 qtrs — |
| 85 | WELLS FARGO & COMPANY/MN | 45.2K +14.4K (+46.7%) | 275.9K -5.7K (-2.0%) | 0.06% +0.020 pp | 0.00% +0.000 pp | USD6.50 -6.0% | 32 qtrs — |
| 86 | LEGAL & GENERAL GROUP PLC | 44.9K -8.2K (-15.5%) | 274.1K -211.7K (-43.6%) | 0.06% -0.012 pp | 0.00% +0.000 pp | USD6.39 -4.4% | 31 qtrs — |
| 87 | SCHONFELD STRATEGIC ADVISORS LLC | 44.8K +30.7K (+217.3%) | 273.4K +144.4K (+111.9%) | 0.06% +0.043 pp | 0.00% +0.001 pp | USD7.07 -13.6% | 2 qtrs — |
| 88 | EMPIRICAL FINANCIAL SERVICES, LLC D.B.A. EMPIRICAL WEALTH MANAGEMENT | 43.9K +43.9K (+100.0%) | 268.4K +268.4K (+100.0%) | 0.06% +0.061 pp | 0.00% +0.005 pp | USD6.11 +0.0% | 1 qtrs NEW |
| 89 | HSBC HOLDINGS PLC | 42.0K +10.6K (+33.8%) | 256.7K -30.3K (-10.6%) | 0.06% +0.015 pp | 0.00% +0.000 pp | USD6.60 -7.4% | 3 qtrs — |
| 90 | CRESSET ASSET MANAGEMENT, LLC | 40.7K +— (+0.0%) | 248.6K -123.7K (-33.2%) | 0.06% 0.000 pp | 0.00% -0.001 pp | USD7.74 -21.1% | 17 qtrs — |
| 91 | STATE OF TENNESSEE, TREASURY DEPARTMENT | 36.4K +13.2K (+56.6%) | 243.9K +31.2K (+14.7%) | 0.05% +0.018 pp | 0.00% +0.000 pp | USD5.91 +3.4% | 5 qtrs — |
| 92 | EXCHANGE TRADED CONCEPTS, LLC | 39.9K +8.5K (+26.9%) | 243.7K -43.9K (-15.3%) | 0.06% +0.012 pp | 0.00% -0.001 pp | USD6.90 -11.4% | 7 qtrs — |
| 93 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 39.4K -829.0 (-2.1%) | 241.0K -127.5K (-34.6%) | 0.06% -0.001 pp | 0.00% 0.000 pp | USD5.93 +3.0% | 31 qtrs — |
| 94 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 39.4K -15.7K (-28.5%) | 240.7K -263.4K (-52.3%) | 0.06% -0.022 pp | 0.00% +0.000 pp | USD7.06 -13.5% | 22 qtrs — |
| 95 | RUSSELL INVESTMENTS GROUP, LTD. | 35.3K +7.5K (+27.2%) | 215.4K -38.1K (-15.0%) | 0.05% +0.011 pp | 0.00% 0.000 pp | USD7.04 -13.2% | 10 qtrs — |
| 96 | OXFORD ASSET MANAGEMENT LLP | 34.8K +34.8K (+100.0%) | 212.5K +212.5K (+100.0%) | 0.05% +0.049 pp | 0.09% +0.087 pp | USD6.11 +0.0% | 5 qtrs — |
| 97 | DEUTSCHE BANK AG\ | 31.5K +1.6K (+5.4%) | 192.5K -81.1K (-29.6%) | 0.04% +0.002 pp | 0.00% +0.000 pp | USD6.33 -3.5% | 31 qtrs — |
| 98 | LINDEN THOMAS ADVISORY SERVICES, LLC | 28.5K -82.0 (-0.3%) | 173.9K -87.3K (-33.4%) | 0.04% 0.000 pp | 0.02% -0.009 pp | USD7.61 -19.7% | 8 qtrs — |
| 99 | WASHINGTON GROWTH STRATEGIES LLC | 26.2K +— (+0.0%) | 160.2K -79.7K (-33.2%) | 0.04% 0.000 pp | 0.10% -0.068 pp | USD6.52 -6.3% | 3 qtrs — |
| 100 | CAMBRIA INVESTMENT MANAGEMENT, L.P. | 25.9K +4.0K (+18.3%) | 158.2K -42.0K (-21.0%) | 0.04% +0.006 pp | 0.01% -0.002 pp | USD5.80 +5.3% | 4 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 78 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Acquirers Small and Micro Deep Value ETF DEEP | 0.85% | 233.0K | 0.80% |
| 2 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.38% | 84.1K | 0.20% |
| 3 | Hartford Multifactor Small Cap ETF ROSC | 0.20% | 120.0K | 0.34% |
| 4 | First Trust Dow Jones Select MicroCap Index Fund FDM | 0.19% | 495.4K | 0.65% |
| 5 | Royce Quant Small-Cap Quality Value ETF SQLV | 0.17% | 48.0K | 0.60% |
| 6 | Vanguard U.S. Multifactor ETF VFMF | 0.09% | 600.8K | 0.18% |
| 7 | Harbor AlphaEdge Small Cap Earners ETF (EBIT) EBIT | 0.08% | 10.0K | 0.29% |
| 8 | Vanguard U.S. Quality Factor ETF VFQY | 0.07% | 328.3K | 0.13% |
| 9 | First Trust Active Factor Small Cap ETF AFSM | 0.07% | 76.9K | 0.75% |
| 10 | WisdomTree U.S. SmallCap Fund EES | 0.06% | 424.6K | 0.38% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.83
Neutral
Ratio by volume
2.24
Bullish
Buys
10
Sells
12
Shares acquired
642.5K
Shares disposed
286.7K
Cash buys
—
Cash sales
—
Net activity
+355,898
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-25 | Miller Larry R. | Officer | M-Exempt | A | Common Stock, par value $.0001 per share | 6,920 | 0.00 | — | 55,438 | D | ↗ |
| 2026-03-13 | Nguyen Diem | Director / Officer | F-InKind | D | Common Stock, par value $.0001 per share | 47,029 | 5.26 | 247.4K | 138,767 | D | ↗ |
| 2026-03-13 | Miller Larry R. | Officer | A-Award | A | Restricted Stock Units | 68,060 | 0.00 | — | 68,060 | D | ↗ |
| 2026-03-13 | Luckshire Daniel J | Officer | M-Exempt | D | Restricted Stock Units | 11,503 | 0.00 | — | 23,008 | D | ↗ |
| 2026-03-13 | Hruby Dennis E | Officer | A-Award | A | Restricted Stock Units | 54,942 | 0.00 | — | 54,942 | D | ↗ |
| 2026-01-27 | Nguyen Diem | Director / Officer | F-InKind | D | Common Stock, par value $.0001 per share | 22,804 | 6.82 | 155.5K | 100,751 | D | ↗ |
| 2025-07-01 | Luckshire Daniel J | Officer | F-InKind | D | Common Stock, par value $.0001 per share | 12,346 | 6.49 | 80.1K | 275,064 | D | ↗ |
| 2025-07-01 | Hruby Dennis E | Officer | M-Exempt | A | Common Stock, par value $.0001 per share | 32,258 | 0.00 | — | 201,514 | D | ↗ |
| 2025-06-10 | Phillips Holly L. | Director | M-Exempt | D | Restricted Stock Units | 19,084 | 0.00 | — | 0 | D | ↗ |
| 2025-06-10 | Nemirovsky Julian | Director | M-Exempt | A | Common Stock, par value $.0001 per share | 19,084 | 0.00 | — | 62,598 | D | ↗ |
| 2025-06-10 | Nabel Gary J. | Director | D-Return | D | Common Stock, par value $.0001 per share | 5,725 | 6.22 | 35.6K | 56,873 | D | ↗ |
| 2025-06-10 | Marshall Joseph W III | Director | D-Return | D | Common Stock, par value $.0001 per share | 5,725 | 6.22 | 35.6K | 229,642 | D | ↗ |
| 2025-06-10 | KEANE JOHN M | Director | A-Award | A | Restricted Stock Units | 24,116 | 0.00 | — | 24,116 | D | ↗ |
| 2025-06-10 | Ford Harold Eugene Jr. | Director | A-Award | A | Restricted Stock Units | 24,116 | 0.00 | — | 24,116 | D | ↗ |
| 2025-06-10 | DURNAN JAYMIE A | Director | D-Return | D | Common Stock, par value $.0001 per share | 5,725 | 6.22 | 35.6K | 71,873 | D | ↗ |
| 2025-04-18 | Miller Larry R. | Officer | M-Exempt | A | Common Stock, par value $.0001 per share | 6,920 | 0.00 | — | 41,976 | D | ↗ |
| 2025-03-25 | Miller Larry R. | Officer | M-Exempt | A | Common Stock, par value $.0001 per share | 6,920 | 0.00 | — | 37,820 | D | ↗ |
| 2025-03-17 | KEANE JOHN M | Director | A-Award | A | Stock Option (Right to buy) | 25,000 | 5.63 | 140.8K | 25,000 | D | ↗ |
| 2025-03-13 | Nguyen Diem | Director / Officer | A-Award | A | Restricted Stock Units | 255,137 | 0.00 | — | 255,137 | D | ↗ |
| 2025-03-13 | Miller Larry R. | Officer | A-Award | A | Restricted Stock Units | 63,784 | 0.00 | — | 63,784 | D | ↗ |
| 2025-03-13 | Luckshire Daniel J | Officer | A-Award | A | Restricted Stock Units | 34,511 | 0.00 | — | 34,511 | D | ↗ |
| 2025-03-13 | Hruby Dennis E | Officer | A-Award | A | Restricted Stock Units | 34,336 | 0.00 | — | 34,336 | D | ↗ |
| 2025-01-27 | Nguyen Diem | Director / Officer | M-Exempt | D | Restricted Stock Units | 55,902 | 0.00 | — | 111,805 | D | ↗ |
| 2024-10-25 | Nguyen Diem | Director / Officer | M-Exempt | D | Performance Stock Units | 59,288 | 0.00 | — | 118,577 | D | ↗ |
| 2024-07-01 | Luckshire Daniel J | Officer | M-Exempt | A | Common Stock, par value $.0001 per share | 24,194 | 0.00 | — | 275,564 | — | ↗ |
| 2024-07-01 | Hruby Dennis E | Officer | M-Exempt | D | Restricted Stock Units | 32,258 | 0.00 | — | 32,258 | — | ↗ |
| 2024-06-11 | Varma Jay | Director / Officer | M-Exempt | A | Common Stock, par value $.0001 per share | 24,712 | 0.00 | — | 24,712 | — | ↗ |
| 2024-06-11 | Phillips Holly L. | Director | M-Exempt | A | Common Stock, par value $.0001 per share | 24,712 | 0.00 | — | 50,928 | — | ↗ |
| 2024-06-11 | Nemirovsky Julian | Director | M-Exempt | A | Common Stock, par value $.0001 per share | 24,712 | 0.00 | — | 50,928 | — | ↗ |
| 2024-06-11 | Nabel Gary J. | Director | M-Exempt | D | Restricted Stock Units | 24,712 | 0.00 | — | 0 | — | ↗ |
| 2024-06-11 | Marshall Joseph W III | Director | A-Award | A | Restricted Stock Units | 19,084 | 0.00 | — | 19,084 | — | ↗ |
| 2024-06-11 | Knisely Evan A. | Director | M-Exempt | A | Common Stock, par value $.0001 per share | 24,712 | 0.00 | — | 24,712 | — | ↗ |
| 2024-06-11 | Ford Harold Eugene Jr. | Director | A-Award | A | Restricted Stock Units | 19,084 | 0.00 | — | 19,084 | — | ↗ |
| 2024-06-11 | DURNAN JAYMIE A | Director | M-Exempt | D | Restricted Stock Units | 24,712 | 0.00 | — | 0 | — | ↗ |
| 2024-03-25 | Miller Larry R. | Officer | A-Award | A | Stock Option (Right to buy) | 25,504 | 8.35 | 213.0K | 25,504 | — | ↗ |
| 2024-01-27 | Nguyen Diem | Director / Officer | A-Award | A | Stock Option (Right to buy) | 219,212 | 5.06 | 1.11M | 219,212 | — | ↗ |
| 2023-06-13 | Varma Jay | Director | A-Award | A | Restricted Stock Units | 24,712 | 0.00 | — | 24,712 | — | ↗ |
| 2023-06-13 | Phillips Holly L. | Director | A-Award | A | Restricted Stock Units | 24,712 | 0.00 | — | 24,712 | — | ↗ |
| 2023-06-13 | Nemirovsky Julian | Director | M-Exempt | D | Restricted Stock Units | 14,620 | 0.00 | — | 0 | — | ↗ |
| 2023-06-13 | Nabel Gary J. | Director | M-Exempt | D | Restricted Stock Units | 14,620 | 0.00 | — | 0 | — | ↗ |
| 2023-06-13 | Marshall Joseph W III | Director | M-Exempt | D | Restricted Stock Units | 14,620 | 0.00 | — | 0 | — | ↗ |
| 2023-06-13 | Knisely Evan A. | Director | A-Award | A | Restricted Stock Units | 24,712 | 0.00 | — | 24,712 | — | ↗ |
| 2023-06-13 | Ford Harold Eugene Jr. | Director | A-Award | A | Restricted Stock Units | 24,712 | 0.00 | — | 24,712 | — | ↗ |
| 2023-06-13 | DURNAN JAYMIE A | Director | M-Exempt | D | Restricted Stock Units | 14,620 | 0.00 | — | 0 | — | ↗ |
| 2023-05-11 | Luckshire Daniel J | Officer | A-Award | A | Restricted Stock Units | 48,387 | 0.00 | — | 48,387 | — | ↗ |
| 2023-05-11 | Hruby Dennis E | Officer | A-Award | A | Restricted Stock Units | 64,516 | 0.00 | — | 64,516 | — | ↗ |
| 2022-11-10 | Varma Jay | — | — | — | — | — | — | — | 0 | — | ↗ |
| 2022-11-10 | Ford Harold Eugene Jr. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-14 | Plansky Michael C. | Director | D-Return | D | Common Stock, par value $.0001 per share | 6,849 | 10.26 | 70.3K | 75,982 | — | ↗ |
| 2022-06-14 | Phillips Holly L. | Director | M-Exempt | A | Common Stock, par value $.0001 per share | 22,831 | 0.00 | — | 22,831 | — | ↗ |
| 2022-06-14 | Nemirovsky Julian | Director | M-Exempt | A | Common Stock, par value $.0001 per share | 22,831 | 0.00 | — | 22,831 | — | ↗ |
| 2022-06-14 | Nabel Gary J. | Director | D-Return | D | Common Stock, par value $.0001 per share | 6,849 | 10.26 | 70.3K | 15,982 | — | ↗ |
| 2022-06-14 | Marshall Joseph W III | Director | D-Return | D | Common Stock, par value $.0001 per share | 6,849 | 10.26 | 70.3K | 188,751 | — | ↗ |
| 2022-06-14 | Kane Julie | Director | M-Exempt | D | Restricted Stock Units | 22,831 | 0.00 | — | 0 | — | ↗ |
| 2022-06-14 | DURNAN JAYMIE A | Director | A-Award | A | Restricted Stock Units | 14,620 | 0.00 | — | 14,620 | — | ↗ |
| 2022-06-14 | Antal James | Director | M-Exempt | D | Restricted Stock Units | 22,831 | 0.00 | — | 0 | — | ↗ |
| 2021-12-09 | Antal James | Director | S-Sale | D | Common Stock, par value $.0001 per share | 30,000 | 7.82 | 234.6K | 100,875 | — | ↗ |
| 2021-07-31 | Luckshire Daniel J | Officer | F-InKind | D | Common Stock, Par Value $.0001 Per Share | 13,902 | 6.37 | 88.6K | 251,370 | — | ↗ |
| 2021-07-31 | Abrams Robin Elizabeth | Officer | M-Exempt | A | Common Stock, Par Value $.0001 Per Share | 26,667 | 0.00 | — | 61,088 | — | ↗ |
| 2021-06-15 | ROSE ERIC A MD | Director | M-Exempt | A | Common Stock, par value $.0001 per share | 15,000 | 0.00 | — | 1,068,593 | — | ↗ |
| 2021-06-15 | Plansky Michael C. | Director | M-Exempt | A | Common Stock, par value $.0001 per share | 15,000 | 0.00 | — | 60,000 | — | ↗ |
| 2021-06-15 | Phillips Holly L. | Director | A-Award | A | Stock Option (Right to buy) | 25,000 | 6.57 | 164.3K | 25,000 | — | ↗ |
| 2021-06-15 | Nemirovsky Julian | Director | A-Award | A | Restricted Stock Units | 22,831 | 0.00 | — | 22,831 | — | ↗ |
| 2021-06-15 | Nabel Gary J. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-15 | Marshall Joseph W III | Director | M-Exempt | A | Common Stock, par value $.0001 per share | 15,000 | 0.00 | — | 172,769 | — | ↗ |
| 2021-06-15 | Kane Julie | Director | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2021-06-15 | DURNAN JAYMIE A | Director | M-Exempt | A | Common Stock, par value $.0001 per share | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2021-06-15 | CONSTANCE THOMAS E | Director | M-Exempt | A | Common Stock, par value $.0001 per share | 15,000 | 0.00 | — | 327,806 | — | ↗ |
| 2021-06-15 | Antal James | Director | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2020-12-10 | Nemirovsky Julian | — | A-Award | A | Stock Option (Right to buy) | 25,000 | 7.00 | 175.0K | 25,000 | — | ↗ |
| 2020-08-27 | Antal James | — | S-Sale | D | Common Stock, Par Value $.0001 Per Share | 30,000 | 7.10 | 213.0K | 115,875 | — | ↗ |
| 2020-08-06 | Taibi Edward P. | — | A-Award | A | Stock Option (Right to buy) | 25,000 | 6.52 | 163.0K | 25,000 | — | ↗ |
| 2020-07-31 | Luckshire Daniel J | — | M-Exempt | A | Common Stock, Par Value $.0001 Per Share | 26,667 | 0.00 | — | 251,610 | — | ↗ |
| 2020-07-31 | Abrams Robin Elizabeth | — | M-Exempt | A | Common Stock, Par Value $.0001 Per Share | 26,667 | 0.00 | — | 48,559 | — | ↗ |
| 2020-06-16 | SAVAS PAUL G | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2020-06-16 | ROSE ERIC A MD | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2020-06-16 | Plansky Michael C. | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2020-06-16 | Marshall Joseph W III | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2020-06-16 | Kane Julie | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2020-06-16 | DURNAN JAYMIE A | — | A-Award | A | Stock Option (Right to buy) | 25,000 | 5.88 | 147.0K | 25,000 | — | ↗ |
| 2020-06-16 | CONSTANCE THOMAS E | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2020-06-16 | Antal James | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2020-05-21 | SAVAS PAUL G | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2020-05-21 | ROSE ERIC A MD | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2020-05-21 | Plansky Michael C. | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2020-05-21 | Marshall Joseph W III | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2020-05-21 | Kane Julie | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2020-05-21 | KINDLER JEFFREY B | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2020-05-21 | CONSTANCE THOMAS E | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2020-05-21 | Antal James | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2019-12-09 | SAVAS PAUL G | — | P-Purchase | A | Common Stock, Par Value $.0001 Per Share | 20,000 | 4.37 | 87.4K | 292,847 | — | ↗ |
| 2019-12-09 | Luckshire Daniel J | — | P-Purchase | A | Common Stock, Par Value $.0001 Per Share | 5,000 | 4.39 | 22.0K | 224,943 | — | ↗ |
| 2019-12-09 | Kane Julie | — | P-Purchase | A | Common Stock, Par Value $.0001 Per Share | 2,500 | 4.39 | 11.0K | 2,500 | — | ↗ |
| 2019-12-09 | Gomez Phillip Louis III | — | P-Purchase | A | Common Stock, Par Value $.0001 Per Share | 10,000 | 4.42 | 44.2K | 475,782 | — | ↗ |
| 2019-11-22 | ROSE ERIC A MD | — | M-Exempt | A | Common Stock, par value $.0001 per share | 100,000 | 0.00 | — | 1,093,094 | — | ↗ |
| 2019-11-22 | Gomez Phillip Louis III | — | F-InKind | D | Common Stock, par value $.0001 per share | 144,028 | 4.92 | 708.6K | 465,782 | — | ↗ |
| 2019-08-23 | SAVAS PAUL G | — | P-Purchase | A | Common Stock, Par Value $.0001 Per Share | 10,000 | 4.95 | 49.5K | 272,847 | — | ↗ |
| 2019-08-09 | SAVAS PAUL G | — | P-Purchase | A | Common Stock, Par Value $.0001 Per Share | 10,000 | 5.08 | 50.8K | 262,847 | — | ↗ |
| 2019-07-31 | Luckshire Daniel J | — | A-Award | A | Common Stock, par value $.0001 per share | 26,666 | 0.00 | — | 232,731 | — | ↗ |
| 2019-07-31 | Abrams Robin Elizabeth | — | A-Award | A | Restricted Stock Units | 53,334 | 0.00 | — | 53,334 | — | ↗ |
| 2019-06-07 | Hruby Dennis E | — | S-Sale | D | Common Stock, Par Value $.0001 Per Share | 16,000 | 5.58 | 89.3K | 147,465 | — | ↗ |
| 2019-06-06 | Hruby Dennis E | — | S-Sale | D | Common Stock, Par Value $.0001 Per Share | 17,000 | 5.57 | 94.7K | 163,645 | — | ↗ |
| 2019-06-05 | Hruby Dennis E | — | S-Sale | D | Common Stock, Par Value $.0001 Per Share | 17,000 | 5.68 | 96.6K | 180,465 | — | ↗ |
| 2019-06-05 | Antal James | — | S-Sale | D | Common Stock, Par Value $.0001 Per Share | 30,000 | 5.70 | 171.0K | 130,875 | — | ↗ |
| 2019-06-04 | BAYER MICHAEL J | — | P-Purchase | A | Common Stock, par value $.0001 per share | 12,500 | 5.74 | 71.8K | 132,244 | — | ↗ |
| 2019-05-22 | SAVAS PAUL G | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2019-05-22 | Plansky Michael C. | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2019-05-22 | Marshall Joseph W III | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2019-05-22 | KINDLER JEFFREY B | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2019-05-22 | CONSTANCE THOMAS E | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2019-05-22 | BAYER MICHAEL J | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2019-05-22 | Antal James | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2019-05-21 | SAVAS PAUL G | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2019-05-21 | ROSE ERIC A MD | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2019-05-21 | Plansky Michael C. | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2019-05-21 | Marshall Joseph W III | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2019-05-21 | Kane Julie | — | A-Award | A | Stock Option (Right to buy) | 25,000 | 5.90 | 147.5K | 25,000 | — | ↗ |
| 2019-05-21 | KINDLER JEFFREY B | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2019-05-21 | CONSTANCE THOMAS E | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2019-05-21 | BAYER MICHAEL J | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2019-05-21 | Antal James | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2019-01-09 | Marshall Joseph W III | — | M-Exempt | A | Common Stock, Par Value $.0001 Per Share | 25,000 | 4.74 | 118.5K | 143,000 | — | ↗ |
| 2018-12-12 | Luckshire Daniel J | — | F-InKind | D | Common Stock, par value $.0001 per share | 28,614 | 6.38 | 182.6K | 206,065 | — | ↗ |
| 2018-11-22 | ROSE ERIC A MD | — | F-InKind | D | Common Stock, par value $.0001 per share | 105,896 | 5.55 | 587.7K | 993,094 | — | ↗ |
| 2018-11-22 | Gomez Phillip Louis III | — | M-Exempt | A | Common Stock, par value $.0001 per share | 588,236 | 0.00 | — | 603,236 | — | ↗ |
| 2018-11-16 | SAVAS PAUL G | — | P-Purchase | A | Common Stock, Par Value $.0001 Per Share | 5,000 | 5.58 | 27.9K | 237,847 | — | ↗ |
| 2018-11-13 | Hruby Dennis E | — | S-Sale | D | Common Stock, Par Value $.0001 Per Share | 31,099 | 5.29 | 164.5K | 197,465 | — | ↗ |
| 2018-11-12 | SAVAS PAUL G | — | P-Purchase | A | Common Stock, Par Value $.0001 Per Share | 10,000 | 5.01 | 50.1K | 232,847 | — | ↗ |
| 2018-11-12 | Hruby Dennis E | — | S-Sale | D | Common Stock, Par Value $.0001 Per Share | 18,901 | 4.96 | 93.7K | 228,564 | — | ↗ |
| 2018-11-12 | Gomez Phillip Louis III | — | P-Purchase | A | Common Stock, Par Value $.0001 Per Share | 15,000 | 5.20 | 78.0K | 15,000 | — | ↗ |
| 2018-10-16 | BAYER MICHAEL J | — | M-Exempt | A | Common Stock, par value $.0001 per share | 25,000 | 3.14 | 78.5K | 134,500 | — | ↗ |
| 2018-09-11 | Hruby Dennis E | — | M-Exempt | D | Stock Option (Right to buy) | 50,000 | 4.70 | 235.0K | 0 | — | ↗ |
| 2018-08-20 | ROSE ERIC A MD | — | M-Exempt | A | Common Stock, par value $.0001 per share | 400,000 | 2.49 | 996.0K | 1,133,267 | — | ↗ |
| 2018-08-20 | Abrams Robin Elizabeth | — | F-InKind | D | Common Stock, par value $.0001 per share | 6,986 | 7.98 | 55.7K | 8,014 | — | ↗ |
| 2018-05-23 | SAVAS PAUL G | — | M-Exempt | A | Common Stock, Par Value $.0001 Per Share | 15,000 | 0.00 | — | 222,847 | — | ↗ |
| 2018-05-23 | Plansky Michael C. | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2018-05-23 | Marshall Joseph W III | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2018-05-23 | KINDLER JEFFREY B | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2018-05-23 | CONSTANCE THOMAS E | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2018-05-23 | BAYER MICHAEL J | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2018-05-23 | Antal James | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2018-05-22 | SAVAS PAUL G | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2018-05-22 | Plansky Michael C. | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2018-05-22 | Marshall Joseph W III | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2018-05-22 | KINDLER JEFFREY B | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2018-05-22 | CONSTANCE THOMAS E | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2018-05-22 | BAYER MICHAEL J | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2018-05-22 | Antal James | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2018-04-18 | Antal James | — | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 3.53 | 35.3K | 0 | — | ↗ |
| 2018-04-17 | CONSTANCE THOMAS E | — | M-Exempt | A | Common Stock, Par Value $.0001 Per Share | 10,000 | 3.53 | 35.3K | 273,500 | — | ↗ |
| 2018-04-16 | SAVAS PAUL G | — | M-Exempt | A | Common Stock, Par Value $.0001 Per Share | 10,000 | 3.53 | 35.3K | 213,504 | — | ↗ |
| 2017-11-13 | ROSE ERIC A MD | — | M-Exempt | A | Common Stock, par value $.0001 per share | 97,785 | 3.53 | 345.2K | 782,713 | — | ↗ |
| 2017-11-10 | Hruby Dennis E | — | F-InKind | D | Common Stock, par value $.0001 per share | 29,439 | 4.60 | 135.4K | 208,140 | — | ↗ |
| 2017-06-08 | Hruby Dennis E | — | D-Return | D | Stock Option (Right to buy) | 200,000 | 3.10 | 620.0K | 100,000 | — | ↗ |
| 2017-05-23 | SAVAS PAUL G | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2017-05-23 | Plansky Michael C. | — | A-Award | A | Stock Option (Right to buy) | 25,000 | 3.50 | 87.5K | 25,000 | — | ↗ |
| 2017-05-23 | Marshall Joseph W III | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2017-05-23 | KINDLER JEFFREY B | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2017-05-23 | CONSTANCE THOMAS E | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2017-05-23 | BAYER MICHAEL J | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2017-05-23 | Antal James | — | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2017-05-17 | STERN ANDREW L | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2017-05-17 | SLOVIN BRUCE | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2017-05-17 | SAVAS PAUL G | — | M-Exempt | A | Common Stock, Par Value $.0001 Per Share | 15,000 | 0.00 | — | 203,504 | — | ↗ |
| 2017-05-17 | Marshall Joseph W III | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2017-05-17 | KINDLER JEFFREY B | — | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2017-05-17 | CONSTANCE THOMAS E | — | M-Exempt | A | Common Stock, Par Value $.0001 Per Share | 15,000 | 0.00 | — | 263,500 | — | ↗ |
| 2017-05-17 | BAYER MICHAEL J | — | M-Exempt | A | Common Stock, Par Value $.0001 Per Share | 15,000 | 0.00 | — | 94,500 | — | ↗ |
| 2017-05-17 | Antal James | — | M-Exempt | A | Common Stock, Par Value $.0001 Per Share | 15,000 | 0.00 | — | 126,487 | — | ↗ |
| 2017-01-03 | ROSE ERIC A MD | — | F-InKind | D | Common Stock, par value $.0001 per share | 29,502 | 2.93 | 86.4K | 684,928 | — | ↗ |
| 2017-01-03 | Luckshire Daniel J | — | M-Exempt | D | Restricted Stock Units | 33,334 | 0.00 | — | 0 | — | ↗ |
| 2017-01-03 | Hruby Dennis E | — | M-Exempt | A | Common Stock, par value $.0001 per share | 25,000 | 0.00 | — | 176,824 | — | ↗ |
| 2016-12-08 | ROSE ERIC A MD | — | M-Exempt | A | Common Stock, par value $.0001 per share | 66,668 | 0.00 | — | 716,232 | — | ↗ |
| 2016-12-08 | Luckshire Daniel J | — | M-Exempt | D | Restricted Stock Units | 33,335 | 0.00 | — | 0 | — | ↗ |
| 2016-12-08 | Hruby Dennis E | — | M-Exempt | A | Common Stock, par value $.0001 per share | 25,000 | 0.00 | — | 147,124 | — | ↗ |
| 2016-11-22 | ROSE ERIC A MD | — | A-Award | A | Restricted Stock Units | 300,000 | 0.00 | — | 300,000 | — | ↗ |
| 2016-11-22 | Gomez Phillip Louis III | — | A-Award | A | Restricted Stock Units | 882,353 | 0.00 | — | 882,353 | — | ↗ |
| 2016-11-16 | STERN ANDREW L | — | M-Exempt | A | Common Stock, Par Value $.0001 Per Share | 715 | 1,072.50 | 766.8K | 62,865 | — | ↗ |
| 2016-11-16 | SLOVIN BRUCE | — | M-Exempt | A | Common Stock, Par Value $.0001 Per Share | 54,167 | 81,250.00 | 4.40B | 179,167 | — | ↗ |
| 2016-11-16 | SAVAS PAUL G | — | M-Exempt | A | Common Stock, Par Value $.0001 Per Share | 66,664 | 99,996.50 | 6.67B | 188,504 | — | ↗ |
| 2016-11-16 | Marshall Joseph W III | — | M-Exempt | A | Common Stock, Par Value $.0001 Per Share | 13,000 | 19,500.00 | 253.50M | 88,000 | — | ↗ |
| 2016-11-16 | MacAndrews & Forbes Inc. | Director / 10% Owner | A-Award | A | Common Stock, Par Value $.0001 Per Share | 565,010 | 2.49 | 1.41M | 24,156,358 | — | ↗ |
| 2016-11-16 | Luckshire Daniel J | — | M-Exempt | A | Common Stock, par value $.0001 per share | 10,000 | 15,000.00 | 150.00M | 114,352 | — | ↗ |
| 2016-11-16 | KINDLER JEFFREY B | — | M-Exempt | A | Common Stock, Par Value $.0001 Per Share | 22,339 | 33,508.50 | 748.55M | 67,339 | — | ↗ |
| 2016-11-16 | CONSTANCE THOMAS E | — | M-Exempt | A | Common Stock, Par Value $.0001 Per Share | 33,500 | 50,250.00 | 1.68B | 248,500 | — | ↗ |
| 2016-11-16 | BAYER MICHAEL J | — | M-Exempt | A | Common Stock, Par Value $.0001 Per Share | 19,500 | 29,250.00 | 570.38M | 79,500 | — | ↗ |
| 2016-11-16 | Antal James | — | M-Exempt | A | Common Stock, Par Value $.0001 Per Share | 30,333 | 45,500.00 | 1.38B | 111,487 | — | ↗ |
| 2016-10-13 | Gomez Phillip Louis III | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-05-17 | STERN ANDREW L | Director | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2016-05-17 | SLOVIN BRUCE | Director | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2016-05-17 | SAVAS PAUL G | Director | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2016-05-17 | Marshall Joseph W III | Director | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2016-05-17 | KINDLER JEFFREY B | Director | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2016-05-17 | CONSTANCE THOMAS E | Director | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2016-05-17 | BAYER MICHAEL J | Director | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2016-05-17 | Antal James | Director | A-Award | A | Restricted Stock Units | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2016-05-14 | STERN ANDREW L | Director | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2016-05-14 | SLOVIN BRUCE | Director | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2016-05-14 | SAVAS PAUL G | Director | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2016-05-14 | Marshall Joseph W III | Director | M-Exempt | D | Restricted Stock Units | 15,000 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
515.3K
Shares Outstanding
71.64M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Diem Nguyen, Ph.D. Chief Executive Officer and Director | 927.0K | 463.5K | 1.85M | — | — | — | 3.24M | 57.14% | ↗ |
| 2 | 2025 | Daniel J. Luckshire Executive Vice President and Chief Financial Officer | 752.3K | 564.2K | 250.8K | — | — | — | 1.57M | 16.00% | ↗ |
| 3 | 2025 | Dennis E. Hruby, Ph.D. Executive Vice President and Chief Scientific Officer | 748.5K | 561.4K | 249.5K | — | — | — | 1.56M | 16.00% | ↗ |
| 4 | 2025 | Larry Miller General Counsel and Corporate Secretary | 695.3K | 347.6K | 463.5K | 32.6K | — | — | 1.54M | 32.24% | ↗ |
| 5 | 2024 | Diem Nguyen, Ph.D. MBA Chief Executive Officer | 835.4K | 900.0K | 1.36M | 1.35M | — | — | 4.45M | 61.00% | ↗ |
| 6 | 2024 | Diem Nguyen, Ph.D. Chief Executive Officer and Director | 835.4K | 900.0K | 1.36M | 1.35M | — | — | 4.45M | 61.00% | ↗ |
| 7 | 2024 | Larry Miller General Counsel & Secretary | 520.3K | 337.5K | 739.8K | 590.4K | — | — | 2.19M | 60.79% | ↗ |
| 8 | 2024 | Larry Miller General Counsel and Corporate Secretary | 520.3K | 337.5K | 739.8K | 590.4K | — | — | 2.19M | 60.79% | ↗ |
| 9 | 2024 | Daniel J. Luckshire Executive Vice President and Chief Financial Officer | 730.3K | 730.3K | — | — | — | — | 1.46M | 0.00% | ↗ |
| 10 | 2024 | Daniel J. Luckshire Executive Vice President, & Chief Financial Officer | 730.3K | 730.3K | — | — | — | — | 1.46M | 0.00% | ↗ |
| 11 | 2024 | Dennis E. Hruby, Ph.D. Executive Vice President & Chief Scientific Officer | 726.7K | 726.7K | — | — | — | — | 1.45M | 0.00% | ↗ |
| 12 | 2024 | Dennis E. Hruby, Ph.D. Executive Vice President and Chief Scientific Officer | 726.7K | 726.7K | — | — | — | — | 1.45M | 0.00% | ↗ |
| 13 | 2024 | Jay K. Varma, M.D. Former Executive Vice President & Chief Medical Officer (employment ended September 2024) | 548.3K | — | — | — | — | — | 548.3K | 0.00% | ↗ |
| 14 | 2024 | Phillip L. Gomez, Ph.D. Former Chief Executive Officer (retired in January 2024) | 71.7K | 66.8K | — | — | — | — | 138.5K | 0.00% | ↗ |
| 15 | 2023 | Phillip L. Gomez, Ph.D. Former Chief Executive Officer (retired in January 2024) | 912.9K | 912.9K | — | — | — | — | 1.83M | 0.00% | ↗ |
| 16 | 2023 | Phillip L. Gomez, Ph.D. Chief Executive Officer | 912.9K | 912.9K | — | — | — | — | 1.83M | 0.00% | ↗ |
| 17 | 2023 | Dennis E. Hruby, Ph.D. Executive Vice President & Chief Scientific Officer | 705.6K | 705.6K | 400.0K | — | — | — | 1.81M | 22.09% | ↗ |
| 18 | 2023 | Dennis E. Hruby, Ph.D. Executive Vice President and Chief Scientific Officer | 705.6K | 705.6K | 400.0K | — | — | — | 1.81M | 22.09% | ↗ |
| 19 | 2023 | Daniel J. Luckshire Executive Vice President, & Chief Financial Officer | 709.1K | 709.1K | 300.0K | — | — | — | 1.72M | 17.46% | ↗ |
| 20 | 2023 | Daniel J. Luckshire Executive Vice President and Chief Financial Officer | 709.1K | 709.1K | 300.0K | — | — | — | 1.72M | 17.46% | ↗ |
| 21 | 2023 | Jay K. Varma, M.D. Former Executive Vice President & Chief Medical Officer (employment ended September 2024) | 244.3K | 242.5K | — | — | — | 183.8K | 670.5K | 0.00% | ↗ |
| 22 | 2023 | Jay K. Varma, M.D. Executive Vice President & Chief Medical Officer | 244.3K | 242.5K | — | — | — | 183.8K | 670.5K | 0.00% | ↗ |
| 23 | 2022 | Phillip L. Gomez, Ph.D. Former Chief Executive Officer (retired in January 2024) | 869.5K | 869.5K | — | — | — | — | 1.74M | 0.00% | ↗ |
| 24 | 2022 | Phillip L. Gomez, Ph.D. Chief Executive Officer | 869.5K | 869.5K | — | — | — | — | 1.74M | 0.00% | ↗ |
| 25 | 2022 | Dennis E. Hruby, Ph.D. Executive Vice President & Chief Scientific Officer | 672.0K | 739.2K | — | — | — | — | 1.41M | 0.00% | ↗ |
| 26 | 2022 | Daniel J. Luckshire Executive Vice President, & Chief Financial Officer | 675.3K | 709.1K | — | — | — | — | 1.38M | 0.00% | ↗ |
| 27 | 2022 | Robin E. Abrams Former General Counsel and Chief Administrative Officer | 186.1K | — | — | — | — | — | 186.1K | 0.00% | ↗ |
| 28 | 2021 | Phillip L. Gomez, Ph.D. Chief Executive Officer | 844.1K | 844.1K | — | — | — | — | 1.69M | 0.00% | ↗ |
| 29 | 2021 | Daniel J. Luckshire Executive Vice President, & Chief Financial Officer | 655.6K | 655.6K | — | — | — | — | 1.31M | 0.00% | ↗ |
| 30 | 2021 | Daniel J. Luckshire Executive Vice President & Chief Financial Officer | 655.6K | 655.6K | — | — | — | — | 1.31M | 0.00% | ↗ |
| 31 | 2021 | Dennis E. Hruby, Ph.D. Executive Vice President & Chief Scientific Officer | 652.4K | 652.4K | — | — | — | — | 1.30M | 0.00% | ↗ |
| 32 | 2021 | Dennis E. Hruby, Ph.D. Vice President & Chief Scientific Officer | 652.4K | 652.4K | — | — | — | — | 1.30M | 0.00% | ↗ |
| 33 | 2021 | Robin E. Abrams General Counsel and Chief Administrative Officer | 619.5K | 619.5K | — | — | — | — | 1.24M | 0.00% | ↗ |
| 34 | 2021 | Robin E. Abrams Former General Counsel and Chief Administrative Officer | 619.5K | 619.5K | — | — | — | — | 1.24M | 0.00% | ↗ |
| 35 | 2020 | Phillip L. Gomez, Ph.D. Chief Executive Officer | 819.5K | 819.5K | — | — | — | — | 1.64M | 0.00% | ↗ |
| 36 | 2020 | Dennis E. Hruby, Ph.D. Executive Vice President & Chief Scientific Officer | 633.4K | 633.4K | — | — | 200.0K | — | 1.47M | 0.00% | ↗ |
| 37 | 2020 | Dennis E. Hruby, Ph.D. Vice President & Chief Scientific Officer | 633.4K | 633.4K | — | — | 200.0K | — | 1.47M | 0.00% | ↗ |
| 38 | 2020 | Daniel J. Luckshire Executive Vice President, & Chief Financial Officer | 636.5K | 636.5K | — | — | — | — | 1.27M | 0.00% | ↗ |
| 39 | 2020 | Daniel J. Luckshire Executive Vice President & Chief Financial Officer | 636.5K | 636.5K | — | — | — | — | 1.27M | 0.00% | ↗ |
| 40 | 2020 | Robin E. Abrams Former General Counsel and Chief Administrative Officer | 551.5K | 551.5K | — | — | — | — | 1.10M | 0.00% | ↗ |
| 41 | 2020 | Robin E. Abrams General Counsel and Chief Administrative Officer | 551.5K | 551.5K | — | — | — | — | 1.10M | 0.00% | ↗ |
| 42 | 2019 | Daniel J. Luckshire Executive Vice President & Chief Financial Officer | 618.0K | 618.0K | 448.0K | — | — | — | 1.68M | 26.60% | ↗ |
| 43 | 2019 | Phillip L. Gomez, Ph.D. Chief Executive Officer | 795.7K | 795.7K | — | — | — | — | 1.59M | 0.00% | ↗ |
| 44 | 2019 | Robin E. Abrams General Counsel and Chief Administrative Officer | 535.4K | 535.4K | 448.0K | — | — | — | 1.52M | 29.50% | ↗ |
| 45 | 2019 | Dennis E. Hruby, Ph.D. Vice President & Chief Scientific Officer | 614.9K | 614.9K | — | — | 200.0K | — | 1.43M | 0.00% | ↗ |
| 46 | 2018 | Phillip L. Gomez, Ph.D. Chief Executive Officer (effective October 13, 2016) | 772.5K | 772.5K | — | — | — | — | 1.55M | 0.00% | ↗ |
| 47 | 2018 | Phillip L. Gomez, Ph.D. Chief Executive Officer | 772.5K | 772.5K | — | — | — | — | 1.55M | 0.00% | ↗ |
| 48 | 2018 | Daniel J. Luckshire Executive Vice President & Chief Financial Officer | 600.0K | 600.0K | — | — | — | — | 1.20M | 0.00% | ↗ |
| 49 | 2018 | Dennis E. Hruby, Ph.D. Vice President & Chief Scientific Officer | 597.0K | 597.0K | — | — | — | — | 1.19M | 0.00% | ↗ |
| 50 | 2018 | Robin E. Abrams General Counsel and Chief Administrative Officer | 519.8K | 519.8K | 119.7K | — | — | — | 1.16M | 10.32% | ↗ |
| 51 | 2018 | Robin E. Abrams General Counsel and Chief Administrative Officer (effective April 12, 2016) | 519.8K | 519.8K | 119.7K | — | — | — | 1.16M | 10.32% | ↗ |
| 52 | 2018 | Eric A. Rose, M.D. Executive Chairman of the Board (until October 13, 2018) Chief Executive Officer (until October 13, 2016) | 551.9K | — | — | — | — | 42.9K | 594.9K | 0.00% | ↗ |
| 53 | 2017 | Phillip L. Gomez, Ph.D. Chief Executive Officer | 750.0K | 912.3K | — | — | — | — | 1.66M | 0.00% | ↗ |
| 54 | 2017 | Phillip L. Gomez, Ph.D. Chief Executive Officer (effective October 13, 2016) | 750.0K | 912.3K | — | — | — | — | 1.66M | 0.00% | ↗ |
| 55 | 2017 | Dennis E. Hruby, Ph.D. Vice President & Chief Scientific Officer | 579.6K | 579.6K | 88.0K | — | — | — | 1.25M | 7.06% | ↗ |
| 56 | 2017 | Daniel J. Luckshire Executive Vice President & Chief Financial Officer | 521.7K | 521.7K | — | — | — | — | 1.04M | 0.00% | ↗ |
| 57 | 2017 | Robin E. Abrams General Counsel and Chief Administrative Officer (effective April 12, 2016) | 504.7K | 504.7K | — | — | — | — | 1.01M | 0.00% | ↗ |
| 58 | 2017 | Robin E. Abrams General Counsel and Chief Administrative Officer | 504.7K | 504.7K | — | — | — | — | 1.01M | 0.00% | ↗ |
| 59 | 2017 | Robin A. Abrams General Counsel and Chief Administrative Officer (effective April 12, 2016) | 504.7K | 504.7K | — | — | — | — | 1.01M | 0.00% | ↗ |
| 60 | 2017 | Eric A. Rose, M.D. Executive Chairman of the Board (effective October 13, 2016) Chief Executive Officer (until October 13, 2016) | 732.2K | — | — | — | — | — | 732.2K | 0.00% | ↗ |
| 61 | 2017 | Eric A. Rose, M.D. Executive Chairman of the Board (until October 13, 2018) Chief Executive Officer (until October 13, 2016) | 732.2K | — | — | — | — | — | 732.2K | 0.00% | ↗ |
| 62 | 2016 | Eric A. Rose, M.D. Executive Chairman of the Board (until October 13, 2018) Chief Executive Officer (until October 13, 2016) | 778.4K | 1.44M | 717.0K | — | — | — | 2.94M | 24.41% | ↗ |
| 63 | 2016 | Eric A. Rose, M.D. Executive Chairman of the Board (effective October 13, 2016) Chief Executive Officer (until October 13, 2016) | 778.4K | 1.44M | 717.0K | — | — | — | 2.94M | 24.41% | ↗ |
| 64 | 2016 | Phillip L. Gomez, Ph.D. Chief Executive Officer (effective October 13, 2016) | 162.5K | — | 2.11M | — | — | — | 2.27M | 92.85% | ↗ |
| 65 | 2016 | Dennis E. Hruby, Ph.D. Vice President & Chief Scientific Officer | 562.8K | 1.41M | — | — | — | — | 1.98M | 0.00% | ↗ |
| 66 | 2016 | Daniel J. Luckshire Executive Vice President & Chief Financial Officer | 506.5K | 1.18M | — | — | — | — | 1.68M | 0.00% | ↗ |
| 67 | 2016 | Robin E. Abrams General Counsel and Chief Administrative Officer (effective April 12, 2016) | 426.9K | 490.0K | — | — | — | — | 916.9K | 0.00% | ↗ |
| 68 | 2016 | Robin A. Abrams General Counsel and Chief Administrative Officer (effective April 12, 2016) | 426.9K | 490.0K | — | — | — | — | 916.9K | 0.00% | ↗ |
| 69 | 2016 | William J. Haynes Executive Vice President & General Counsel (Resigned, effective January 5, 2016) | 5.6K | 242.3K | — | — | — | — | 247.9K | 0.00% | ↗ |
| 70 | 2015 | Eric A. Rose, M.D. Executive Chairman of the Board (effective October 13, 2016) Chief Executive Officer (until October 13, 2016) | 764.9K | — | — | — | — | — | 764.9K | 0.00% | ↗ |
| 71 | 2015 | Eric A. Rose, M.D. Chief Executive Officer | 764.9K | — | — | — | — | — | 764.9K | 0.00% | ↗ |
| 72 | 2015 | Dennis E. Hruby, Ph.D. Vice President & Chief Scientific Officer | 546.4K | — | — | — | — | — | 546.4K | 0.00% | ↗ |
| 73 | 2015 | (Resigned, effective January 5, 2016) Dennis E. Hruby, Ph.D. Vice President & Chief Scientific Officer | 546.4K | — | — | — | — | — | 546.4K | 0.00% | ↗ |
| 74 | 2015 | William J. Haynes Executive Vice President & General Counsel (Resigned, effective January 5, 2016) | 491.7K | — | — | — | — | — | 491.7K | 0.00% | ↗ |
| 75 | 2015 | William J. Haynes Executive Vice President & General Counsel | 491.7K | — | — | — | — | — | 491.7K | 0.00% | ↗ |
| 76 | 2015 | Daniel J. Luckshire Executive Vice President & Chief Financial Officer | 450.2K | — | — | — | — | — | 450.2K | 0.00% | ↗ |
| 77 | 2014 | Eric A. Rose, M.D. Executive Chairman of the Board (effective October 13, 2016) Chief Executive Officer (until October 13, 2016) | 743.1K | — | 670.0K | — | — | — | 1.41M | 47.41% | ↗ |
| 78 | 2014 | Eric A. Rose, M.D. Chief Executive Officer | 743.1K | — | 670.0K | — | — | — | 1.41M | 47.41% | ↗ |
| 79 | 2014 | Eric A. Rose, M.D. Chief Executive Officer | 743.1K | — | 670.0K | — | — | — | 1.41M | 47.41% | ↗ |
| 80 | 2014 | Dennis E. Hruby, Ph.D. Vice President & Chief Scientific Officer | 530.5K | — | 251.3K | — | — | — | 781.7K | 32.14% | ↗ |
| 81 | 2014 | (Resigned, effective January 5, 2016) Dennis E. Hruby, Ph.D. Vice President & Chief Scientific Officer | 530.5K | — | 251.3K | — | — | — | 781.7K | 32.14% | ↗ |
| 82 | 2014 | Dennis E. Hruby, Ph.D. Vice President Chief Scientific Officer | 530.5K | — | 251.3K | — | — | — | 781.7K | 32.14% | ↗ |
| 83 | 2014 | Daniel J. Luckshire Executive Vice President & Chief Financial Officer | 437.1K | — | 335.0K | — | — | — | 772.1K | 43.39% | ↗ |
| 84 | 2014 | Daniel J. Luckshire Executive Vice President Chief Financial Officer | 437.1K | — | 335.0K | — | — | — | 772.1K | 43.39% | ↗ |
| 85 | 2014 | William J. Haynes Executive Vice President & General Counsel (Resigned, effective January 5, 2016) | 477.4K | — | 251.3K | — | — | — | 728.7K | 34.48% | ↗ |
| 86 | 2014 | William J. Haynes Executive Vice President General Counsel | 477.4K | — | 251.3K | — | — | — | 728.7K | 34.48% | ↗ |
| 87 | 2014 | William J. Haynes Executive Vice President & General Counsel | 477.4K | — | 251.3K | — | — | — | 728.7K | 34.48% | ↗ |
| 88 | 2013 | Eric A. Rose, M.D. Chief Executive Officer | 721.0K | 360.5K | 564.0K | — | — | 500.00 | 1.65M | 34.26% | ↗ |
| 89 | 2013 | Eric A. Rose, M.D. Chief Executive Officer | 721.0K | 360.5K | 564.0K | — | — | 500.00 | 1.65M | 34.26% | ↗ |
| 90 | 2013 | (Resigned, effective January 5, 2016) Dennis E. Hruby, Ph.D. Vice President & Chief Scientific Officer | 515.0K | 257.5K | 211.5K | — | — | — | 984.0K | 21.49% | ↗ |
| 91 | 2013 | Dennis E. Hruby, Ph.D. Vice President Chief Scientific Officer | 515.0K | 257.5K | 211.5K | — | — | — | 984.0K | 21.49% | ↗ |
| 92 | 2013 | Daniel J. Luckshire Executive Vice President Chief Financial Officer | 424.4K | 212.2K | 282.0K | — | — | — | 918.5K | 30.70% | ↗ |
| 93 | 2013 | William J. Haynes Executive Vice President | 450.0K | 225.0K | 211.5K | — | — | — | 886.5K | 23.86% | ↗ |
| 94 | 2013 | William J. Haynes Executive Vice President General Counsel | 450.0K | 225.0K | 211.5K | — | — | — | 886.5K | 23.86% | ↗ |
| 95 | 2013 | William J. Haynes Executive Vice President & General Counsel | 450.0K | 225.0K | 211.5K | — | — | — | 886.5K | 23.86% | ↗ |
| 96 | 2013 | Ayelet Dugary Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 97 | 2012 | Eric A. Rose, M.D. Chief Executive Officer | 700.0K | 350.0K | 594.0K | — | — | — | 1.85M | 32.18% | ↗ |
| 98 | 2012 | Dennis E. Hruby, Ph.D. Vice President Chief Scientific Officer | 500.0K | 500.0K | 222.8K | 187.2K | — | — | 1.41M | 29.07% | ↗ |
| 99 | 2012 | Daniel J. Luckshire Executive Vice President & Chief Financial Officer | 424.4K | 212.2K | 282.0K | — | — | — | 918.5K | 30.70% | ↗ |
| 100 | 2012 | Daniel J. Luckshire Executive Vice President | 400.0K | 200.0K | 104.0K | 197.3K | — | — | 901.3K | 33.43% | ↗ |
| 101 | 2012 | Daniel J. Luckshire Executive Vice President Chief Financial Officer | 400.0K | 200.0K | 104.0K | 197.3K | — | — | 901.3K | 33.43% | ↗ |
| 102 | 2012 | William J. Haynes Executive Vice President General Counsel | 260.8K | 225.0K | — | 157.2K | — | — | 643.0K | 24.45% | ↗ |
| 103 | 2012 | William J. Haynes Executive Vice President General Counsel | 260.8K | 225.0K | — | 157.2K | — | — | 643.0K | 24.45% | ↗ |
| 104 | 2012 | William J. Haynes Executive Vice President | 260.8K | 225.0K | — | 157.2K | — | — | 643.0K | 24.45% | ↗ |
| 105 | 2012 | Ayelet Dugary Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 106 | 2011 | Eric A. Rose, M.D. Chief Executive Officer | 400.0K | 1.00M | 6.97M | — | — | — | 8.37M | 83.27% | ↗ |
| 107 | 2011 | Daniel J. Luckshire Executive Vice President | 356.1K | 200.0K | — | 877.1K | — | — | 1.43M | 61.20% | ↗ |
| 108 | 2011 | Daniel J. Luckshire Executive Vice President Chief Financial Officer | 356.1K | 200.0K | — | 877.1K | — | — | 1.43M | 61.20% | ↗ |
| 109 | 2011 | Chief Financial Officer | 356.1K | 200.0K | — | 258.5K | — | — | 814.6K | 31.74% | ↗ |
| 110 | 2011 | Dennis E. Hruby, Ph.D. Chief Scientific Officer | 335.8K | 350.0K | — | 61.0K | — | — | 746.8K | 8.16% | ↗ |
| 111 | 2011 | Dennis E. Hruby, Ph.D. Vice President Chief Scientific Officer | 335.8K | 350.0K | — | — | — | — | 685.8K | 0.00% | ↗ |
| 112 | 2011 | Ayelet Dugary Chief Financial Officer | 225.0K | 50.0K | — | — | — | — | 275.0K | 0.00% | ↗ |
| 113 | 2010 | Dennis E. Hruby, Ph.D. Chief Scientific Officer | 275.0K | 150.0K | — | 111.2K | — | — | 536.2K | 20.74% | ↗ |
| 114 | 2010 | Dennis E. Hruby, Ph.D. Vice President Chief Scientific Officer | 275.0K | 150.0K | — | — | — | — | 425.0K | 0.00% | ↗ |
| 115 | 2010 | Eric A. Rose, M.D. Chief Executive Officer | 400.0K | — | — | — | — | — | 400.0K | 0.00% | ↗ |
| 116 | 2010 | Ayelet Dugary Chief Financial Officer | 225.0K | 50.0K | — | — | — | — | 275.0K | 0.00% | ↗ |
| 117 | 2009 | Eric A. Rose, M.D. Chief Executive Officer | 400.0K | — | — | — | — | — | 881.1K | 0.00% | ↗ |
| 118 | 2009 | Dennis E. Hruby, Ph.D. Chief Scientific Officer | 275.0K | 150.0K | — | — | — | — | 643.8K | 0.00% | ↗ |
| 119 | 2009 | Ayelet Dugary Chief Financial Officer | 225.0K | 50.0K | — | — | — | — | 355.7K | 0.00% | ↗ |
| 120 | 2009 | Thomas N. Konatich Former Chief Financial Officer | 40.1K | — | — | — | — | 125.0K | 165.1K | 0.00% | ↗ |
| 121 | 2008 | Dennis E. Hruby, Ph.D. Chief Scientific Officer | 250.0K | 125.0K | — | — | — | — | 567.7K | 0.00% | ↗ |
| 122 | 2008 | Eric A. Rose, M.D. Chief Executive Officer | 400.0K | — | — | 166.9K | — | — | 566.9K | 29.45% | ↗ |
| 123 | 2008 | Thomas N. Konatich Former Chief Financial Officer | 250.0K | 60.0K | — | — | — | — | 310.0K | 0.00% | ↗ |
| 124 | 2008 | Thomas N. Konatich Chief Financial Officer | 250.0K | 60.0K | — | — | — | — | 310.0K | 0.00% | ↗ |
| 125 | 2008 | Ayelet Dugary Chief Financial Officer | 180.0K | 40.0K | — | 46.9K | — | — | 266.9K | 17.58% | ↗ |
| 126 | 2008 | Ayelet Dugary Acting Chief Financial Officer | 180.0K | 40.0K | — | — | — | — | 220.0K | 0.00% | ↗ |
| 127 | 2008 | Bernard L. Kasten Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 128 | 2007 | Dennis E. Hruby, Ph.D. Chief Scientific Officer | 250.0K | 125.0K | — | — | — | — | 924.3K | 0.00% | ↗ |
| 129 | 2007 | Eric A. Rose, M.D. Chief Executive Officer | 333.8K | — | — | — | — | — | 699.9K | 0.00% | ↗ |
| 130 | 2007 | Thomas N. Konatich Chief Financial Officer | 250.0K | 60.0K | — | 274.6K | — | — | 584.6K | 46.98% | ↗ |
| 131 | 2007 | Thomas N. Konatich Former Chief Financial Officer | 250.0K | 60.0K | — | — | — | — | 584.6K | 0.00% | ↗ |
| 132 | 2007 | Ayelet Dugary Chief Financial Officer | 180.0K | 40.0K | — | — | — | — | 265.8K | 0.00% | ↗ |
| 133 | 2007 | Ayelet Dugary Acting Chief Financial Officer | 180.0K | 40.0K | — | 45.8K | — | — | 265.8K | 17.22% | ↗ |
| 134 | 2007 | Bernard L. Kasten Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 135 | 2006 | Dennis E. Hruby, Ph.D. Chief Scientific Officer | 229.2K | 174.5K | — | — | — | — | 403.7K | 0.00% | ↗ |
| 136 | 2006 | Thomas N. Konatich Chief Financial Officer | 233.3K | 117.5K | — | — | — | — | 350.8K | 0.00% | ↗ |
| 137 | 2006 | Ayelet Dugary Acting Chief Financial Officer | 150.0K | 40.0K | — | — | — | — | 190.0K | 0.00% | ↗ |
| 138 | 2006 | Bernard L. Kasten Chief Executive Officer | 83.3K | — | — | — | — | 94.8K | 178.1K | 0.00% | ↗ |
| 139 | 2006 | Eric A. Rose, M.D. Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 140 | 2005 | Thomas N. Konatich Chief Financial Officer | 230.0K | 35.0K | — | — | — | — | 265.0K | 0.00% | ↗ |
| 141 | 2005 | Bernard L. Kasten Chief Executive Officer | 250.0K | — | — | — | — | — | 250.0K | 0.00% | ↗ |
| 142 | 2005 | Eric A. Rose, M.D. Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Diem Nguyen | Chief Executive Officer & Director | 1M | — |
| Daniel J. Luckshire | Executive Vice President, Chief Financial Officer & Secretary | 1M | male |
| Dennis E. Hruby | Executive Vice President & Chief Scientific Officer | 1M | — |
| Lawrence Miller | General Counsel & Corporate Secretary | 1M | male |
| Herb Vloedman | Senior Vice President & Chief Information Officer | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SIGA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
